Idorsia’s hypertension lifeline

Regaining commercial rights to one of the assets included in the $30 billion takeout of Actelion could provide Idorsia with the lifeline it needs to change investor sentiment about its growth prospects, and help it access much-needed equity capital.

Idorsia Ltd. (SIX:IDIA) has been beset by a growing financial crisis for much of the year. In its 2022 full-year results announced in February, Idorsia provided 2023 guidance of CHF650 million ($703.4 million) in operating expenses, but just CHF466 million in cash, giving the Swiss biotech less than nine months of runway...